Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Agnes B. Fogo is active.

Publication


Featured researches published by Agnes B. Fogo.


American Journal of Transplantation | 2008

Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

Kim Solez; Robert B. Colvin; Lorraine C. Racusen; Mark Haas; B. Sis; Michael Mengel; Philip F. Halloran; William M. Baldwin; Giovanni Banfi; A. B. Collins; F. Cosio; Daisa Silva Ribeiro David; Cinthia B. Drachenberg; G. Einecke; Agnes B. Fogo; Ian W. Gibson; Samy S. Iskandar; Edward S. Kraus; Evelyne Lerut; Roslyn B. Mannon; Michael J. Mihatsch; Brian J. Nankivell; Volker Nickeleit; John C. Papadimitriou; Parmjeet Randhawa; Heinz Regele; Karine Renaudin; Ian S.D. Roberts; Daniel Serón; R. N. Smith

The 9th Banff Conference on Allograft Pathology was held in La Coruna, Spain on June 23–29, 2007. A total of 235 pathologists, clinicians and scientists met to address unsolved issues in transplantation and adapt the Banff schema for renal allograft rejection in response to emerging data and technologies. The outcome of the consensus discussions on renal pathology is provided in this article. Major updates from the 2007 Banff Conference were: inclusion of peritubular capillaritis grading, C4d scoring, interpretation of C4d deposition without morphological evidence of active rejection, application of the Banff criteria to zero‐time and protocol biopsies and introduction of a new scoring for total interstitial inflammation (ti‐score). In addition, emerging research data led to the establishment of collaborative working groups addressing issues like isolated ‘v’ lesion and incorporation of omics‐technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process.


Journal of The American Society of Nephrology | 2004

The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited

Jan J. Weening; Melvin M. Schwartz; Surya V. Seshan; Charles E. Alpers; Gerald B. Appel; James E. Balow; Jan A. Bruijn; Terence Cook; Franco Ferrario; Agnes B. Fogo; Ellen M. Ginzler; Lee A. Hebert; Gary S. Hill; Prue Hill; J. Charles Jennette; N. C T Kong; Philippe Lesavre; Michael D. Lockshin; Looi Lm; Hirofumi Makino; Luiz Antonio Ribeiro de Moura; Michio Nagata

The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving <50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving > or =50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.


American Journal of Transplantation | 2003

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection.

Lorraine C. Racusen; Robert B. Colvin; Kim Solez; Michael J. Mihatsch; Philip F. Halloran; Patricia Campbell; Michael Cecka; Jean-Pierre Cosyns; Anthony J. Demetris; Michael C. Fishbein; Agnes B. Fogo; Peter N. Furness; Ian W. Gibson; Pekka Häyry; Lawrence Hunsickern; Michael Kashgarian; Ronald H. Kerman; Alex Magil; Robert A. Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; D. Serón; Surya V. Seshan; Ståle Sund; Kiril Trpkov

Antibody‐mediated rejection (AbAR) is increasingly recognized in the renal allograft population, and successful therapeutic regimens have been developed to prevent and treat AbAR, enabling excellent outcomes even in patients highly sensitized to the donor prior to transplant. It has become critical to develop standardized criteria for the pathological diagnosis of AbAR. This article presents international consensus criteria for and classification of AbAR developed based on discussions held at the Sixth Banff Conference on Allograft Pathology in 2001. This classification represents a working formulation, to be revisited as additional data accumulate in this important area of renal transplantation.


Kidney International | 2009

The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification

Daniel C. Cattran; Rosanna Coppo; H. Terence Cook; John Feehally; Ian S.D. Roberts; Stéphan Troyanov; Charles E. Alpers; Alessandro Amore; Jonathan Barratt; François Berthoux; Stephen M. Bonsib; Jan A. Bruijn; Giuseppe D'Amico; Steven N. Emancipator; Francesco Emma; Franco Ferrario; Fernando C. Fervenza; Sandrine Florquin; Agnes B. Fogo; Colin C. Geddes; Hermann Josef Groene; Mark Haas; Andrew M. Herzenberg; Prue Hill; Ronald J. Hogg; Stephen I-Hong Hsu; J. Charles Jennette; Kensuke Joh; Bruce A. Julian; Tetsuya Kawamura

IgA nephropathy is the most common glomerular disease worldwide, yet there is no international consensus for its pathological or clinical classification. Here a new classification for IgA nephropathy is presented by an international consensus working group. The goal of this new system was to identify specific pathological features that more accurately predict risk of progression of renal disease in IgA nephropathy, thus enabling both clinicians and pathologists to improve individual patient prognostication. In a retrospective analysis, sequential clinical data were obtained on 265 adults and children with IgA nephropathy who were followed for a median of 5 years. Renal biopsies from all patients were scored by pathologists blinded to the clinical data for pathological variables identified as reproducible by an iterative process. Four of these variables: (1) the mesangial hypercellularity score, (2) segmental glomerulosclerosis, (3) endocapillary hypercellularity, and (4) tubular atrophy/interstitial fibrosis were subsequently shown to have independent value in predicting renal outcome. These specific pathological features withstood rigorous statistical analysis even after taking into account all clinical indicators available at the time of biopsy as well as during follow-up. The features have prognostic significance and we recommended they be taken into account for predicting outcome independent of the clinical features both at the time of presentation and during follow-up. The value of crescents was not addressed due to their low prevalence in the enrolled cohort.


Kidney International | 2009

The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility

Ian S.D. Roberts; H. Terence Cook; Stéphan Troyanov; Charles E. Alpers; Alessandro Amore; Jonathan Barratt; François Berthoux; Stephen M. Bonsib; Jan A. Bruijn; Daniel C. Cattran; Rosanna Coppo; Giuseppe D'Amico; Steven N. Emancipator; Francesco Emma; John Feehally; Franco Ferrario; Fernando C. Fervenza; Sandrine Florquin; Agnes B. Fogo; Colin C. Geddes; Hermann Josef Groene; Mark Haas; Andrew M. Herzenberg; Prue Hill; Ronald J. Hogg; Stephen I-Hong Hsu; J. Charles Jennette; Kensuke Joh; Bruce A. Julian; Tetsuya Kawamura

Pathological classifications in current use for the assessment of glomerular disease have been typically opinion-based and built on the expert assumptions of renal pathologists about lesions historically thought to be relevant to prognosis. Here we develop a unique approach for the pathological classification of a glomerular disease, IgA nephropathy, in which renal pathologists first undertook extensive iterative work to define pathologic variables with acceptable inter-observer reproducibility. Where groups of such features closely correlated, variables were further selected on the basis of least susceptibility to sampling error and ease of scoring in routine practice. This process identified six pathologic variables that could then be used to interrogate prognostic significance independent of the clinical data in IgA nephropathy (described in the accompanying article). These variables were (1) mesangial cellularity score; percentage of glomeruli showing (2) segmental sclerosis, (3) endocapillary hypercellularity, or (4) cellular/fibrocellular crescents; (5) percentage of interstitial fibrosis/tubular atrophy; and finally (6) arteriosclerosis score. Results for interobserver reproducibility of individual pathological features are likely applicable to other glomerulonephritides, but it is not known if the correlations between variables depend on the specific type of glomerular pathobiology. Variables identified in this study withstood rigorous pathology review and statistical testing and we recommend that they become a necessary part of pathology reports for IgA nephropathy. Our methodology, translating a strong evidence-based dataset into a working format, is a model for developing classifications of other types of renal disease.


Journal of The American Society of Nephrology | 2010

Pathologic Classification of Diabetic Nephropathy

Thijs W. Cohen Tervaert; Antien L. Mooyaart; Kerstin Amann; Arthur H. Cohen; H. Terence Cook; Cinthia B. Drachenberg; Franco Ferrario; Agnes B. Fogo; Mark Haas; Emile de Heer; Kensuke Joh; Laure Hélène Noël; Jai Radhakrishnan; Surya V. Seshan; Ingeborg M. Bajema; Jan A. Bruijn

Although pathologic classifications exist for several renal diseases, including IgA nephropathy, focal segmental glomerulosclerosis, and lupus nephritis, a uniform classification for diabetic nephropathy is lacking. Our aim, commissioned by the Research Committee of the Renal Pathology Society, was to develop a consensus classification combining type1 and type 2 diabetic nephropathies. Such a classification should discriminate lesions by various degrees of severity that would be easy to use internationally in clinical practice. We divide diabetic nephropathy into four hierarchical glomerular lesions with a separate evaluation for degrees of interstitial and vascular involvement. Biopsies diagnosed as diabetic nephropathy are classified as follows: Class I, glomerular basement membrane thickening: isolated glomerular basement membrane thickening and only mild, nonspecific changes by light microscopy that do not meet the criteria of classes II through IV. Class II, mesangial expansion, mild (IIa) or severe (IIb): glomeruli classified as mild or severe mesangial expansion but without nodular sclerosis (Kimmelstiel-Wilson lesions) or global glomerulosclerosis in more than 50% of glomeruli. Class III, nodular sclerosis (Kimmelstiel-Wilson lesions): at least one glomerulus with nodular increase in mesangial matrix (Kimmelstiel-Wilson) without changes described in class IV. Class IV, advanced diabetic glomerulosclerosis: more than 50% global glomerulosclerosis with other clinical or pathologic evidence that sclerosis is attributable to diabetic nephropathy. A good interobserver reproducibility for the four classes of DN was shown (intraclass correlation coefficient = 0.84) in a test of this classification.


Journal of Clinical Investigation | 2000

Bone morphogenetic protein 4 regulates the budding site and elongation of the mouse ureter

Yoichi Miyazaki; Keisuke Oshima; Agnes B. Fogo; Brigid L.M. Hogan; Iekuni Ichikawa

In the normal mouse embryo, Bmp4 is expressed in mesenchymal cells surrounding the Wolffian duct (WD) and ureter stalk, whereas bone morphogenetic protein (BMP) type I receptor genes are transcribed either ubiquitously (Alk3) or exclusively in the WD and ureter epithelium (Alk6). Bmp4 heterozygous null mutant mice display, with high penetrance, abnormalities that mimic human congenital anomalies of the kidney and urinary tract (CAKUT), including hypo/dysplastic kidneys, hydroureter, ectopic ureterovesical (UV) junction, and double collecting system. Analysis of mutant embryos suggests that the kidney hypo/dysplasia results from reduced branching of the ureter, whereas the ectopic UV junction and double collecting system are due to ectopic ureteral budding from the WD and accessory budding from the main ureter, respectively. In the cultured metanephros deprived of sulfated glycosaminoglycans (S-GAGs), BMP4-loaded beads partially rescue growth and elongation of the ureter. By contrast, when S-GAGs synthesis is not inhibited, BMP4 beads inhibit ureter branching and expression of Wnt 11, a target of glial cell-derived neurotrophic factor signaling. Thus, Bmp4 has 2 functions in the early morphogenesis of the kidney and urinary tract. One is to inhibit ectopic budding from the WD or the ureter stalk by antagonizing inductive signals from the metanephric mesenchyme to the illegitimate sites on the WD. The other is to promote the elongation of the branching ureter within the metanephros, thereby promoting kidney morphogenesis.


Molecular Cell | 1999

Role of the Angiotensin Type 2 Receptor Gene in Congenital Anomalies of the Kidney and Urinary Tract, CAKUT, of Mice and Men

Hideki Nishimura; Elizabeth B. Yerkes; Katharina Hohenfellner; Yoichi Miyazaki; Ji Ma; Tracy E. Hunley; Hiroaki Yoshida; Toshihiro Ichiki; David W. Threadgill; John A. Phillips; Brigid M.L Hogan; Agnes B. Fogo; John W. Brock; Tadashi Inagami; Iekuni Ichikawa

Angiotensin type 2 receptor gene null mutant mice display congenital anomalies of the kidney and urinary tract (CAKUT). Various features of mouse CAKUT impressively mimic human CAKUT. Studies of the human type 2 receptor (AGTR2) gene in two independent cohorts found that a significant association exists between CAKUT and a nucleotide transition within the lariat branchpoint motif of intron 1, which perturbs AGTR2 mRNA splicing efficiency. AGTR2, therefore, has a significant ontogenic role for the kidney and urinary tract system. Studies revealed that the establishment of CAKUT is preceded by delayed apoptosis of undifferentiated mesenchymal cells surrounding the urinary tract during key ontogenic events, from the ureteral budding to the expansive growth of the kidney and ureter.


Journal of Clinical Investigation | 1989

Glomerular actions of endothelin in vivo.

Valentina Kon; Toshimasa Yoshioka; Agnes B. Fogo; Iekuni Ichikawa

In Munich-Wistar rats, a micropipette was inserted into a first-order branch of the left main renal artery and continuously infused with human/porcine endothelin (0.4 ng/min). Micropuncture measurements revealed substantial differences within the cortical microcirculation of the same left kidney: SNGFR was some 35% lower in glomeruli exposed to endothelin compared with non-endothelin-perfused glomeruli (P less than 0.005). Similarly, glomerular plasma flow rate was some 38% lower in the endothelin-exposed glomeruli (P less than 0.001). The hypoperfusion and hypofiltration in the endothelin-exposed glomeruli reflected an increase in resistances in the afferent and efferent arterioles. There was no difference in the value of the glomerular capillary ultrafiltration coefficient between the two populations of glomeruli. We also studied kidneys that underwent 25 min of renal artery clamping 48 h before study. Antiendothelin antibody infused into one of the branches of the main renal artery ameliorated the vasoconstriction characteristic of postischemic nephrons: within the cortical microcirculation, the SNGFR in glomeruli exposed to antiendothelin antibody was 27.0 +/- 3.1 nl/min as compared with 17.4 +/- 1.7 measured in glomeruli not perfused with the antibody (P less than 0.001). Similarly, glomerular plasma flow rate was higher in the glomeruli exposed to antiendothelin antibody (128.7 +/- 14.4 nl/min vs. 66.6 +/- 5.6, P less than 0.005). Resistances in both the afferent and efferent arterioles were substantially lower in the antibody-exposed glomeruli. It is, therefore, suggested that endothelin, presumably released from damaged endothelium, may play an important intermediary role in the hypoperfusion and hypofiltration observed in postischemic kidneys.


Journal of Clinical Investigation | 1995

Gene Targeting in Mice Reveals a Requirement for Angiotensin in the Development and Maintenance of Kidney Morphology and Growth Factor Regulation

F Niimura; Patricia A. Labosky; Junji Kakuchi; Soichiro Okubo; Hiroaki Yoshida; T Oikawa; Toshihiro Ichiki; A J Naftilan; Agnes B. Fogo; Tadashi Inagami

Elevated levels of endogenous angiotensin can cause hypertensive nephrosclerosis as a result of the potent vasopressor action of the peptide. We have produced by gene targeting mice homozygous for a null mutation in the angiotensinogen gene (Atg-1-). Postnatally, Atg-1- animals show a modest delay in glomerular maturation. Although Atg-1- animals are hypotensive by 7 wk of age, they develop, by 3 wk of age, pronounced lesions in the renal cortex, similar to those of hypertensive nephrosclerosis. In addition, the papillae of homozygous mutant kidneys are reduced in size. These lesions are accompanied by local up-regulation of PDGF-B and TGF-beta1 mRNA in the cortex and down-regulation of PDGF-A mRNA in the papilla. The study demonstrates an important requirement for angiotensin in achieving and maintaining the normal morphology of the kidney. The mechanism through which angiotensin maintains the volume homeostasis in mammals includes promotion of the maturational growth of the papilla.

Collaboration


Dive into the Agnes B. Fogo's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Valentina Kon

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Haichun Yang

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Li-Jun Ma

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Charles Jennette

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge